Related Experiment Video
Updated: Feb 13, 2026

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience
Published on: December 4, 2023
Prevention of Subsequent L-Asparaginase Hypersensitivity in Children Through Premedication: A Single-Center
Pongsathorn Saligupta1, Chane Choed-Amphai1, Lalita Sathitsamitphong1
1Division of Allergy and Clinical Immunology (PS, ML), Division of Pediatric Hematology and Oncology (CC, LS), Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Insights
A premedication protocol safely enabled continued L-asparaginase therapy for children with ALL who experienced severe hypersensitivity reactions. This approach improves chemotherapy access in resource-limited settings.
Area of Science:
- Pediatric Oncology
- Pharmacology
- Clinical Immunology
Background:
- L-asparaginase is crucial for treating pediatric acute lymphoblastic leukemia (ALL).
- Hypersensitivity reactions to L-asparaginase necessitate alternative treatments, which may be unavailable in resource-limited areas.
- Native *Escherichia coli* L-asparaginase is a common formulation, but severe reactions can occur.
Purpose of the Study:
- To assess the safety and feasibility of a premedication protocol.
- To prevent hypersensitivity reactions in children with a history of severe reactions to native *E. coli* L-asparaginase.
- To enable continued L-asparaginase therapy in resource-limited settings.
Main Methods:
- Retrospective cohort study of 119 children with ALL.
- Identified 10 patients (8.4%) with severe systemic hypersensitivity reactions.
- Administered a premedication protocol including oral prednisolone, cetirizine, montelukast, and intravenous hydrocortisone before subsequent L-asparaginase doses.
Main Results:
- 76 subsequent L-asparaginase doses were administered after premedication.
- 7 recurrent hypersensitivity reactions (9.2%) occurred in 6 patients, mostly mild.
- All patients completed their L-asparaginase therapy, with one requiring epinephrine for a severe reaction.
Conclusions:
- The premedication protocol showed potential for safely continuing native *E. coli* L-asparaginase therapy.
- This strategy may improve chemotherapy access for children with ALL in resource-limited settings.
- Further research can validate this approach for managing L-asparaginase hypersensitivity.
Objective:
L-asparaginase is an essential component of pediatric acute lymphoblastic leukemia (ALL) treatment. However, hypersensitivity reactions can occur, necessitating a switch to alternative asparaginase formulations. In resource-limited settings, access to pegylated asparaginase and Erwinia asparaginase may be limited. This study aimed to evaluate the safety and feasibility of a premedication protocol in preventing subsequent L-asparaginase hypersensitivity reactions in children with a history of severe reactions to native Escherichia coli L-asparaginase.
Methods:
A retrospective cohort study was conducted in 119 children with ALL treated with L-asparaginase at Chiang Mai University Hospital. Ten patients (8.4%) developed severe systemic hypersensitivity reactions. Subsequent intramuscular L-asparaginase doses were preceded by a standardized premedication protocol comprising oral prednisolone, cetirizine, and montelukast, along with preinfusion intravenous hydrocortisone.
Results:
A total of 76 subsequent L-asparaginase doses were administered following premedication. Seven episodes (9.2%) of recurrent hypersensitivity reactions occurring within 5 to 40 minutes of L-asparaginase dosing occurred in 6 patients. Most reactions were mild and managed with additional antihistamines and corticosteroids. One episode required treatment with intramuscular epinephrine. All patients successfully completed their prescribed course of L-asparaginase therapy.
Conclusion:
In resource-limited settings, our premedication protocol demonstrated potential for safely enabling continued native E. coli L-asparaginase therapy in children with a history of severe hypersensitivity reactions, thus potentially improving access to chemotherapy treatment.
Related Concept Videos
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Hypersensitivity Reactions: Cytolytic Reactions
Center of Gravity
Center of Gravity
To determine its location, the principle of moments can be utilized by dividing the object into...

